EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma

MLA

Xiang Zhou, et al. “EASIX-Guided Risk Stratification for Complications and Outcome after CAR T-Cell Therapy with Ide-Cel in Relapsed/Refractory Multiple Myeloma.” Journal for ImmunoTherapy of Cancer, vol. 12, no. 10, Oct. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2024-009220.

APA

Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, Hartmut Goldschmidt, Hermann Einsele, Nikhil C Munshi, Marc S Raab, Joseph Kauer, Thomas Hielscher, Niels Weinhold, Mirco J Friedrich, Sandra Sauer, Leo Rasche, Thomas Luft, Jan H Frenking, … Adam S Sperling. (2024). EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. Journal for ImmunoTherapy of Cancer, 12(10). https://doi.org/10.1136/jitc-2024-009220

Chicago

Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, et al. 2024. “EASIX-Guided Risk Stratification for Complications and Outcome after CAR T-Cell Therapy with Ide-Cel in Relapsed/Refractory Multiple Myeloma.” Journal for ImmunoTherapy of Cancer 12 (10). doi:10.1136/jitc-2024-009220.